Stephen F. Betz, Ph.D., is a distinguished scientist and the Chief Scientific Officer at Crinetics Pharmaceuticals, Inc. With a robust background in biochemistry and molecular biology, Dr. Betz has dedicated his career to advancing the field of drug discovery and development. He earned his Ph.D. from the University of California, Berkeley, where his research focused on protein structure and function. Following his doctoral studies, Dr. Betz completed a postdoctoral fellowship at the Scripps Research Institute, further honing his expertise in molecular biology. Before joining Crinetics Pharmaceuticals, Dr. Betz held significant roles at several leading biotech companies, including Amgen and Neurocrine Biosciences. At these organizations, he was instrumental in the development of novel therapeutic agents, contributing to multiple successful drug launches. His work has been widely published in peer-reviewed journals, and he is recognized as an authority in the design and optimization of small molecule drugs. Dr. Betz's transition to Crinetics Pharmaceuticals as Chief Scientific Officer has been pivotal, as he spearheads the company's research and development efforts, particularly in the area of endocrine diseases. In his current role at Crinetics Pharmaceuticals, Dr. Betz is responsible for overseeing the scientific strategy and execution of the company's pipeline, which includes several promising drug candidates targeting rare endocrine disorders. His leadership has been crucial in advancing these candidates through various stages of clinical trials, bringing hope to patients with limited treatment options. Under his guidance, Crinetics has fostered a culture of innovation and excellence, positioning the company as a leader in the development of novel therapies for endocrine-related conditions. Dr. Betz's strategic vision and scientific acumen continue to drive Crinetics Pharmaceuticals toward its mission of improving patient lives through groundbreaking research and development.